EPCAM and neoplasm: BLI demonstrated that the tumor burden in mice receiving the anti-EpCAM RNA CAR treatment was obviously reduced relative to the initial tumor burdens and that the inhibition of tumour growth by repeated injections of the anti-EpCAM RNA CAR-modified T cells maintained during the 3-week treatment period in all treated mice (Figure 7B).